NewcelX (NCEL) Non-Current Assets (2019 - 2025)
NewcelX (NCEL) posted quarterly Non-Current Assets of $8.3 million for Q4 2025, up 6617.89% year-over-year from $123000.0 in Q4 2024, and up 7695.28% quarter-over-quarter from $106000.0 in Q2 2025.
NewcelX (NCEL) Non-Current Assets (2019 - 2025) Analysis & Trends
NewcelX (NCEL) has reported Non-Current Assets for 7 consecutive years, with $8.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets rose 6617.89% year-over-year to $8.3 million; the TTM figure through Dec 2025 stood at $8.3 million (up 6617.89% YoY), while the FY2025 annual figure was $8.3 million, up 6617.89% from the prior year.
- Non-Current Assets grew to $8.3 million in Q4 2025 per NCEL's latest filing, from $106000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $8.3 million in Q4 2025 and bottomed at $27733.0 in Q2 2021.
- Historically, Non-Current Assets has averaged $1.2 million across 5 years, with a median of $191000.0 in 2024.
- Annual changes were most pronounced in 2021 — Non-Current Assets slumped 95.91% — and 2025, when it jumped 6617.89%.
- NewcelX's Non-Current Assets stood at $41554.0 in 2021, then jumped by 3367.78% to $1.4 million in 2022, then tumbled by 50.73% to $710000.0 in 2023, then tumbled by 82.68% to $123000.0 in 2024, then surged by 6617.89% to $8.3 million in 2025.
- Business Quant data shows NCEL's Non-Current Assets at $8.3 million in Q4 2025, $106000.0 in Q2 2025, and $123000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | NewcelX | 12.54 Mn | 10.34 Mn | - | 8.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.26 Mn |
| Jun 30, 2025 | 106,000.00 |
| Dec 31, 2024 | 123,000.00 |
| Jun 30, 2024 | 259,000.00 |
| Dec 31, 2023 | 710,000.00 |
| Jun 30, 2023 | 1.05 Mn |
| Dec 31, 2022 | 1.44 Mn |
| Jun 30, 2022 | 35,541.00 |
| Dec 31, 2021 | 41,554.00 |
| Jun 30, 2021 | 27,733.00 |
| Dec 31, 2020 | 1.01 Mn |
| Dec 31, 2019 | 314,683.00 |